2,479 reports of this reaction
2.5% of all VENETOCLAX reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for VENETOCLAX, manufactured by AbbVie Inc.. There are 2,479 FDA adverse event reports linking VENETOCLAX to FATIGUE. This represents approximately 2.5% of all 98,823 adverse event reports for this drug.
VENETOCLAX has an overall safety score of 88 out of 100. Patients taking VENETOCLAX who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for VENETOCLAX, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for VENETOCLAX:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,479 FDA reports for VENETOCLAX. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.5% of all adverse event reports for VENETOCLAX, making it a notable side effect.
If you experience fatigue while taking VENETOCLAX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.